Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08HQK
|
|||
| Former ID |
DAP001431
|
|||
| Drug Name |
Tetracaine
|
|||
| Synonyms |
Amethocaine; Anetain; Contralgin; Dicain; Dicaine; Dikain; Fissucain; Intercain; Laudocaine; Medicaine; Meethobalm; Metraspray; Mucaesthin; Niphanoid; Pontocaine; Rexocaine; Tetracaina; Tetracainum; Tetrakain; Uromucaesthin; Tetrakain [Czech]; Amethocaine (TN); Diaethylaminoaethanol ester der p-butylaminobenzoesaeure;Diaethylaminoaethanol ester der p-butylaminobenzoesaeure [German]; Medihaler-Tetracaine; Pontocaine (TN); Tetracaina [INN-Spanish]; Tetracaine [USAN:INN]; Tetracainum [INN-Latin]; Dimethylaminoethyl p-butyl-aminobenzoate; Tetracaine (USP/INN); P-Butylaminobenzoyl-2-dimethylaminoethanol; BENZOIC ACID,4-BUTYLAMINO,2-DIMETHYLAMINOETHYL ESTER PANTOCAIN BASE; P-(Butylamino)benzoic acid, 2-(dimethylamino)ethyl ester; BENZOIC ACID, p-(BUTYLAMINO)-, 2-(DIMETHYLAMINO)ETHYL ESTER; Benzoic acid, 4-(butylamino)-, 2-(dimethylamino)ethyl ester; 2-(Dimethylamino)ethyl 4-(butylamino)benzoate; 2-(Dimethylamino)ethyl p-(butylamino)benzoate; 2-Dimethylaminoethylester kyseliny p-butylaminobenzoove; 2-Dimethylaminoethylester kyseliny p-butylaminobenzoove [Czech]; 2-dimethylaminoethyl 4-(butylamino)benzoate; 4-(Butylamino)benzoic acid 2-(dimethylamino)ethyl ester; 4-[Butylamino]benzoic acid-2-[dimethylamino]ethyl ester
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Spinal anesthesia [ICD-11: MB40.3; ICD-10: R20.0, R20.1; ICD-9: 338] | Approved | [1] | |
| Pain [ICD-11: MG30-MG3Z] | Phase 2 | [2] | ||
| Therapeutic Class |
Anesthetics
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H24N2O2
|
|||
| Canonical SMILES |
CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C
|
|||
| InChI |
1S/C15H24N2O2/c1-4-5-10-16-14-8-6-13(7-9-14)15(18)19-12-11-17(2)3/h6-9,16H,4-5,10-12H2,1-3H3
|
|||
| InChIKey |
GKCBAIGFKIBETG-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 94-24-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9729, 588146, 5641339, 7847617, 7980764, 8153329, 10538471, 11111916, 11111917, 11335782, 11361021, 11363926, 11366488, 11369050, 11371544, 11373920, 11377212, 11461993, 11466599, 11467719, 11485191, 11486337, 11489144, 11490378, 11492166, 11494846, 15221665, 24900174, 24900448, 29224463, 47291115, 47885396, 47885397, 47885398, 47959731, 48035103, 48259217, 48334477, 49698891, 49886256, 50111267, 50602921, 57309767, 57322762, 57654695, 85089751, 85171696, 85787844, 88826460, 90340576
|
|||
| ChEBI ID |
CHEBI:9468
|
|||
| ADReCS Drug ID | BADD_D02176 ; BADD_D02177 | |||
| SuperDrug ATC ID |
C05AD02; D04AB06; N01BA03; S01HA03
|
|||
| SuperDrug CAS ID |
cas=000094246
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Voltage-gated sodium channel alpha Nav1.8 (SCN10A) | Target Info | Inhibitor | [3] |
| Reactome | Interaction between L1 and Ankyrins | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Evaluation of a novel topical anesthetic agent for cutaneous laser resurfacing: a randomized comparison study. Dermatol Surg. 2002 Nov;28(11):1004-6; discussion 1006. | |||
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 3 | Heterologous expression and functional analysis of rat Nav1.8 (SNS) voltage-gated sodium channels in the dorsal root ganglion neuroblastoma cell line ND7-23. Neuropharmacology. 2004 Mar;46(3):425-38. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.